Blue Jet Healthcare Ltd.
BLUEJET · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹256.54.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%19.9%
- ✓Low debt (D/E < 0.5)0.03x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-31%
- ✕Earnings growing-42%
- ✓Net margin ≥ 10%26.2%
- ✓Current ratio > 1.54.21
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 20.71
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (19.9%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (26.2%).
- •Financially solid — Altman Z 20.71.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Well off its 52-week high — possible mean-reversion.
Threats
- •Earnings contracting year on year.
- •Trades ~36% above our estimated fair value.
About Blue Jet Healthcare Ltd.
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.